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Abstract The t(7;11)(p15;p15.4) has been reported to fuse the NUP98 gene (11p15), a component of the
nuclear pore complex, with the class-1 homeobox gene HOXA9 at 7p15. This translocation has
been associated with myeloid leukemias, predominantly acute myeloid leukemia (AML) M2 subtype
with trilineage myelodysplastic features, and with a poor prognosis. The derived fusion protein
retains the FG repeat motif of NUP98 N-terminus and the homeodomain shared by the HOX genes,
acting as an oncogenic transcription factor critical for leukemogenesis. We report here a new complex
t(7;11)-variant, i.e., t(7;11;13;17)(p15;p15;p?;p1?2) in a patient with AML-M2 and poor prognosis.
The NUP98-HOXA9 fusion transcript was detected by RT-PCR, suggesting its role in the malignant
transformation as it has been postulated for other t(7;11)-associated leukemias. No other fusion
transcripts involving the NUP98 or HOXA9 genes were present, although other mechanisms involving
several genes on chromosomes 13 and 17 may also be involved. To our knowledge, this is the first
t(7;11) variant involving NUP98 described in hematological malignancies.  2005 Elsevier Inc.
All rights reserved.1. Introduction
The t(7;11)(p15;p15) is a rare but recurrent chromosome
abnormality found in myeloid malignancies: mainly acute
myeloid leukemia (AML) but also myelodysplastic syn-
drome (MDS) and chronic myelogenous leukemia (CML)
[1,2]. There are some morphological features associated with
this translocation, including predominantly the AML-M2
subtype with trilineage myelodisplastic features, and a poor
prognosis [3–5]. This translocation has been observed in
Asian people more frequently [3–5].
In this translocation, the NUP98 gene (11p15.4), which
codes for a component of the nuclear pore complex that
* Corresponding author. Tel:34-948-425600; fax:34-948-425649.
E-mail address: ilahortiga@unav.es (I. Lahortiga).0165-4608/05/$ – see front matter  2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.cancergencyto.2004.08.001regulates nucleocytoplasmic transport of RNA and proteins,
is fused to the class-1 homeobox gene HOXA9 (7p15) [6,7].
The homeobox (HOX) genes encode transcription factors that
act as morphogenetic regulatory molecules essential in the
patterning of the development of many segmental and axial
structures in several organisms. Expression of the HOX
genes in hematopoietic cells results in differences in lineage
commitment and maturation, with a decreasing expression
as commitment to a specific lineage occurs [8].
The NUP98-HOXA9 fusion transcript is thought to be
the leukemogenic event in the t(7;11)-associated leukemias,
because the chimeric protein derived retains important struc-
tural motifs such as the NUP98 N-terminal FG repeat motif,
and the HOXA9 C-terminal part which contains the DNA
binding homeodomain shared by the HOX genes. The struc-
ture of this fusion suggested that the homeodomain expres-
sion is upregulated [9–11].
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6 class-1 homeobox genes: HOXD13 (2q31) [12], HOXD11
(2q31) [13], HOXA13 (7p15) [14,15], HOXA11 (7p15) [15],
HOXC11 (12q13) [16], and HOXC13 (12q13) [17]; and to
the class-2 homeobox gene PMX1 (1q23) [18].
Here we report a new complex t(7;11) variant transloca-
tion, t(7;11;13;17)(p15;p15;p?;p1?2) in a patient with AML-
M2 and poor prognosis. The NUP98-HOXA9 fusion tran-
script detected in our patient might be responsible for the
malignant transformation, as it has been postulated in other
t(7;11)-associated leukemias.
2. Materials and methods
2.1. Case report
A 76-year-old Caucasian woman was admitted in Febru-
ary of 1998, with cough and expectoration with no fever,
lasting for a month, and disnea and bleeding expectoration.
Pallor, systolic heart murmur, and edemas were found in the
physical exploration along with the following hematological
findings: 15.3 × 109/L leukocytes (48% neutrophils, 15%
lymphocytes, 1% monocyte, 36% blasts); hemoglobin 8.4
g/dL; hematocrite 22.7%; and platelets 29 × 109/L. The co-
agulation study, as well as the biochemical and hepatical
analysis were normal. Bone marrow (BM) aspirate showed
72% blast cells with 90% positivity for myeloperoxidase
and weak PAS positive result. No Auer rods were present.
Although the immunophenotype was compatible with acute
promyelocytic leukemia (CD33, CD117, and MPO, with a
weak CD34 and a low HLA-DR), the complete clinical
evaluation was consistent with a diagnosis of AML-M2, so,
the patient received therapy with idarubicin and cytarabine.
However the clinical condition continued worsening. The pa-
tient showed respiratory insufficiency, edemas in the lower
extremities, blasts in peripheral blood which became worse,
contracted renal insufficiency, multiorganic failure, and fi-
nally died one month after diagnosis.
2.2. Conventional and molecular cytogenetics
Conventional karyotyping was performed on un-stimu-
lated short-term BM cultures. G-banded analysis showed 2
abnormal clones: 46,XX,t(7;11)(p15;p15),del(17)(p12)[37]/
47,XX,idem,8[13]. The karyotype was described ac-
cording to the ISCN 1995 [19]. Fluorescence in situ hybrid-
ization (FISH) studies were performed using 2 BAC clones
from the RPCI (Roswell Park Cancer Institute, Buffalo, NY)
libraries (http://www.chori.org/bacpac/): RP11 348A20,
spanning exons 1 to 26 of NUP98, and RP11 555F1, located
in a region ~600 Kb telomeric to NUP98, labeled with
Spectrum Orange and Spectrum Green (Vysis, Downers
Grove, IL), respectively. Due to the results obtained and in
order to further define the chromosomes involved in the
rearrangement, the following probes were also used: BACs
RP11 199F11 and RP11 404G1, covering the TP53 locus(17p13.2); PAC RP5 1112G21, spanning the CDC6, RARa,
and TOP2A genes (17q21.2); and 2 alphoid clones for the
centromeres of chromosomes 13 and of chromosome 17.
The clones were labeled with Spectrum Green, Spectrum
Orange (Vysis), or DEAC (NEL 455; Perkin-Elmer Life
Sciences Inc, Boston, MA), by nick translation. FISH analy-
sis was performed on BM metaphases as previously de-
scribed [20]. Samples were obtained from the patient with
informed consent.
2.3. Nucleic acid isolation
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) from frozen cell pellets of leuke-
mic cells. DNA from BAC, PAC, and alphoid clones was
extracted using Qiaprep Spin Miniprep kit (Qiagen).
2.4. Rapid amplification of cDNA ends (RACE)
polymerase chain reaction (PCR)
A 5′ and 3′ RACE-PCR was performed with the Gen-
eRacer Kit (Invitrogen Life Technologies, Paisley, UK) and
with the SMART RACE cDNA amplification kit (Clontech,
Basingstoke, UK) according to the manufacturers’ indica-
tions. NUP98 specific forward primers: NUP98-1 and
NUP98-2 (internal to NUP98-1), were used in a first and a
nested PCR reactions, respectively for the 3′RACE-PCR.
The reverse primers: NUP98-5 and NUP98-3 (internal to
NUP98-5), were used in a first and a nested PCR reactions,
respectively for the 5′RACE-PCR. Both transcript variants of
HOXA9 were considered when designing the primers for the
3′RACE. Two sets of primes were used: HOXA9-1 with
HOXA9-2 (internal to HOXA9-1), and HOXA9-2 with
HOXA9-3 (internal to HOXA9-2), used in a first and a
nested PCR reactions, respectively. The sequences of the
primers are shown in Table 1.
2.5. Reverse transcriptase-PCR
One microgram each of total RNA from the BM cells of
the patient and from a healthy donor were used for cDNA
synthesis using SuperScript II RNase H- RT (Invitrogen Life
Technologies, Paisley, UK) with random hexamers. RT-PCR
reactions were carried out with AmpliTaq Gold DNA poly-
merase (Applied Biosystems, Foster City, CA), with the
same conditions described above. To confirm the presence of
the NUP98-HOXA9 fusion product, RT-PCR was performed
with sense NUP98-6 and antisense HOXA9-4 primers
(Table 1).
2.6. DNA cloning and sequencing
PCR products from the RACE and RT-PCR experiments
were subcloned using the TOPO TA Cloning Kit for sequenc-
ing (Invitrogen Life Technologies). Colonies with recombi-
nant plasmids containing the PCR products were screened
by digestion with EcoR I (Amersham Biosciences, Bucking-
hamshire, UK). Candidate plasmid clones were sequenced
I. Lahortiga et al. / Cancer Genetics and Cytogenetics 157 (2005) 151–156 153
Table 1
Oligonucleotide primer sequences
Primer Oligonucleotide sequence (5′-3′) Gene Nucleotidesa
NUP98-1 TAAACCAGCACCTGGGACTCTTGGAAC NUP98 1391-1417
NUP98-2 TGGGGCCCCTGGATTTAATACTACGA NUP98 1520-1545
NUP98-3 CTGGGCTGCTGGATTTGTTG NUP98 1748-1729
NUP98-5 TTCATCGTCATCCAGCCCATC NUP98 1874-1854
NUP98-6 TTGGGGCCCCTGGATTTAATACTAC NUP98 1519-1543
HOXA9-1 GGCCCTGGGCAACTACTACGTGGA HOXA9 88-111
HOXA9-2 CCCGCTGCGGTGTACCACCACCATC HOXA9 308-332
HOXA9-3 GCCGGCCTTATGGCATTAAACCTGAAC HOXA9 453-449
HOXA9-4 CCTGCGGTCCCTGGTGAGGT HOXA9 781-762
a Nucleotide coordinates refer to GenBank accession numbers NM-016320.2 (NUP98) and NM-152739.2 (HOXA9).with ABI-PRISM d-Rhodamine Terminator Cycle Sequenc-
ing Kit (Applied Biosystems) in an ABI PRISM 377 DNA
sequencer (Applied Biosystems).
3. Results and discussion
FISH analysis in a patient with AML-M2 and
t(7;11)(p15;p15) at the G-band level was performed with
BAC RP11 348A20. This clone showed a split signal on the
der(11) and in the short arm of the der(17), indicating that
NUP98 was disrupted as a result of a cryptic translocation
not detected at the G-band level (Fig. 1A I). Moreover,
FISH analysis performed with selected probes specific for
chromosomes 13 and 17 (Figs. 1A II, III, and IV), allowed
to define a cryptic t(7;11;13;17)(p15;p15;p?;p1?2) complex
translocation present in the patient cells. A diagram of the
variant translocation is shown in Fig. 1B.
In order to identify the partner gene of NUP98, we per-
formed 3′ RACE-PCR experiments on reverse-transcribed
RNA isolated from the BM of the patient. The 3′ RACE-
PCR product showed a sequence fused to exon 12 of NUP98
that perfectly matched the gene HOXA9, mapped on chromo-
some band 7p15. The resultant in-frame chimeric mRNA
joined exon 12 of NUP98 to exon 1B of HOXA9. The 5′
RACE-PCR experiments showed no new sequences on 17p
fused to NUP98. No new sequences on 13p fused to HOXA9
were found by 3′ RACE. These results might suggest that
the translocation lead to the loss of the 5′ portion of NUP98
gene, the 3′ portion of HOXA9, or both. Otherwise, lack
of detection of transcripts containing these gene sequences
might indicate either there are no transcripts expressed or
that the resulting transcript are unstable and rapidly degraded
in the case of the HOXA9 gene, that conserved its promoter.
RT-PCR experiments using primers flanking the NUP98-
HOXA9 transcript fusion showed a 281 bp product (Fig. 2A).
Sequence analysis of this product confirmed the NUP98-
HOXA9 in-frame fusion, with the breakpoints (BP) located
between exons 12 and 13 of NUP98, and between exons
1A and 1B of HOXA9 (Fig. 2B). This fusion transcript
is predicted to encode a protein of 578 amino acids. The
HOXA9 BP in the t(7;11) occurs in all cases previouslyreported between exons 1A and 1B, separating the homeodo-
main encoded by exon 2 from the regulatory elements
located in exon 1A [2]. The BP on NUP98 has been reported
to lie in either intron 12 or intron 11 leading to either the most
frequent NUP98-HOXA9 type I fusion, the one we detected
in our patient, or to the less common NUP98-HOXA9 type
II fusion, respectively [1,2].
The NUP98-HOXA9 fusion transcript detected in our pa-
tient might be responsible for the malignant transformation,
as it has been postulated in other cases with t(7;11) involving
NUP98. This chimeric transcript is thought to be the critical
event in the leukemic transformation of patients with NUP98
and HOXA9 rearrangements because it retains important
structural motifs [6,7]. Firstly, the FG repeats located in
the N-terminus of the NUP98 protein are retained in all
the NUP98 fusion proteins reported, suggesting that these
repeats exert an important function in the leukemic transfor-
mation. Noteworthy, the FG repeats have been shown to
activate transcription and interact with both CREBBP and
p300 [18]. In addition, the nucleoporin fusions could contrib-
ute to leukemogenesis because they alter nuclear transport.
Secondly, the 3′ homeodomain shared by the HOX genes is
also present in the chimeric protein suggesting that it would
be upregulated. Interestingly, overexpression of Hoxa9 in
murine BM cells is able to induce AML after a latency period
[21], and constitutive expression of Hoxa9 immortalizes
myeloid progenitors in vitro [22]. Expression profile experi-
ments have demonstrated that HOXA9 is frequently overex-
pressed in AML cells and this finding has been associated
with poor prognosis [23]. NUP98-HOXA9 seems to act as an
oncogenic transcription factor critical for leukemogenesis
[2,18]. Moreover, mice transplanted with BM cells ex-
pressing NUP98-HOXA9 through retroviral transduction de-
velop a myeloproliferative disease and eventually succumb
to AML, a progression that is accelerated if Meis1 (a Pbx-
related ‘orphan’ homebox gene) is co-expressed [21]. Be-
sides, it has been postulated that NUP98-HOXA9 may
cause leukemic transformation by interfering with myeloid
differentiation.
The abnormal nuclear location of the fusion protein inside
of the nucleus, instead of the normal NUP98 localization at
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Fig. 1. (A) FISH analysis of a patient with t(7;11;13;17). (I) RP11 348A20 probe (red), that covers NUP98, labels normal chromosome 11, der(11) and
der(17). RP11 555F1 (green), located ~600 Kb telomeric to NUP98, labels normal chromosome 11 and der(17). (II) RP11 348A20 probe (red), labels
normal chromosome 11, der(11) and der(17). RP5 1112G21 probe (green), that covers CDC6, RARa and TOP2A labels normal chromosome 17 and der(17).
(III) BACs RP11 199F11 and RP11 404G1 that cover the TP53 (red) label normal chromosome 17 and der(13). Chromosome 17 centromere probe
(green) labels normal chromosome 17 and der(17). (IV) BACs RP11 199F11 and RP11 404G1 that cover the TP53 (red) label normal chromosome 17 and
the der(13). Chromosome 13 centromere probe (green) labels normal chromosome 13 and the der(13). (B) Ideograms of the chromosomes involved displaying the
relative location of the breakpoints, the different fragments which were rearranged to generate the complex aberration, and the genes involved.
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Fig. 2. Molecular analysis of the NUP98-HOXA9 fusion in the patient. (A) RT-PCR showing amplification of the NUP98-HOXA9 fusion product in bone
marrow of the patient (lane 1) but not in normal bone marrow (lane 2). M: 1 Kb plus DNA Ladder. Lane 3: negative control. (B) Schematic representation
of the breakpoint (arrow) and the fusion transcript derived. NUP98 exon 12 sequence (bold) is followed by HOXA9 exon 1B (italics).the nuclear rim [24,25], suggests that inappropriate interac-
tions with key transcriptional regulatory proteins required
for myeloid differentiation may occur [26].
No other fusion transcripts involving NUP98 or HOXA9
were detected in our patient, confirming the crucial role
suggested for the NUP98-HOXA9 transcript in the oncogen-
esis. Interestingly, our patient shows a diagnosis of AML-
M2 and a poor prognosis, both features highly associated
with t(7;11)-associated leukemias. However, the 5′ portion
of the NUP98 gene or the 3′ portion of HOXA9 might be
loss or not expressed in this complex translocation, and
we can not obviate that other molecular mechanism involv-
ing chromosomes 13 and 17 might contribute to the leuke-
mia. Moreover, the presence of a complex rearrangement
might also correlate with the poor prognosis showed by
the patient.
In conclusion, we report a new complex t(7;11;13;17) in
a patient with AML-M2 that had a poor prognosis, features
highly associated with the classical t(7;11). To our knowl-
edge, this is the first t(7;11) variant described in hematol-
ogical malignancies. The NUP98-HOXA9 type I fusion
transcript is present in our patient, confirming its role in the
leukemic transformation. No other fusion transcripts were
detected, although other genomic events involving chromo-
somes 13 and 17 can not been excluded. Further studies will
provide new insights into the specific mechanism of this
complex translocation in leukemogenesis.
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